论文部分内容阅读
在系统性红斑狼疮(SLE)患者中,有40%～80%的患者有肾脏受累的临床表现。狼疮性肾炎(LN)严重影响狼疮患者的生存率,约20%的LN患者于10年内发展为尿毒症。在过去的几十年对LN的治疗已经开展了很多临床研究,发现了许多有效药物,但在免疫抑制剂的使用上尚未有比较一致的观点,对这些研究进行回顾性分析,提出更合理的治疗LN研究方案,在临床工作中要根据每例患者具体病情等制订个体化治疗方案尤为重要。
In patients with systemic lupus erythematosus (SLE), 40% to 80% of patients have clinical manifestations of renal involvement. Lupus nephritis (LN) severely affects the survival rate of patients with lupus, about 20% of LN patients develop uremia within 10 years. There have been many clinical studies on the treatment of LN in the past few decades and many effective drugs have been found. However, there has not been a consensus on the use of immunosuppressive drugs. The retrospective analysis of these studies suggests that more rational Treatment of LN research programs, in clinical work according to each patient’s specific condition, such as the development of individualized treatment programs is particularly important.